Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

ACAT inhibition and the progression of coronary atherosclerosis.

Rudel LL, Farese RV Jr.

N Engl J Med. 2006 Jun 15;354(24):2616-7; author reply 2616-7. No abstract available.

2.

Failure of ACAT inhibition to retard atherosclerosis.

Fazio S, Linton M.

N Engl J Med. 2006 Mar 23;354(12):1307-9. No abstract available.

PMID:
16554534
3.

Effect of ACAT inhibition on the progression of coronary atherosclerosis.

Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators..

N Engl J Med. 2006 Mar 23;354(12):1253-63. Erratum in: N Engl J Med. 2006 Aug 10;355(6):638.

4.

Carotid atherosclerosis progression and ACAT inhibition.

Parini P, Eriksson M, Rudel LL.

JAMA. 2009 Jul 15;302(3):255; author reply 256-7. doi: 10.1001/jama.2009.1000. No abstract available.

PMID:
19602681
5.

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.

Nicholls SJ, Sipahi I, Schoenhagen P, Wisniewski L, Churchill T, Crowe T, Goormastic M, Wolski K, Tuzcu EM, Nissen SE; ACTIVATE Investigators..

Am Heart J. 2006 Jul;152(1):67-74.

PMID:
16824833
6.

Atherosclerosis drug fails to meet Phase III trial end point.

[No authors listed]

Nat Rev Drug Discov. 2009 May;8(5):348. doi: 10.1038/nrd2879. No abstract available.

PMID:
19404306
7.

[New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects].

Wiklund O.

Lakartidningen. 2006 Oct 25-31;103(43):3270. Swedish. No abstract available.

PMID:
17117657
8.

Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits.

Kitayama K, Koga T, Maeda N, Inaba T, Fujioka T.

Eur J Pharmacol. 2006 Jun 6;539(1-2):81-8.

PMID:
16690054
9.
10.

Eflucimibe. Pierre Fabre/Eli Lilly.

Burnett JR.

Curr Opin Investig Drugs. 2003 Mar;4(3):347-51. Review.

PMID:
12735237
11.

Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?

Heinonen TM.

Curr Atheroscler Rep. 2002 Jan;4(1):65-70. Review.

PMID:
11772425
12.

Human ACAT-1 and ACAT-2 inhibitory activities of pentacyclic triterpenes from the leaves of Lycopus lucidus TURCZ.

Lee WS, Im KR, Park YD, Sung ND, Jeong TS.

Biol Pharm Bull. 2006 Feb;29(2):382-4.

13.

The nine lives of ACAT inhibitors.

Farese RV Jr.

Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1684-6. Review. No abstract available.

14.

Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.

Miyazaki A, Sakai M, Sakamoto Y, Horiuchi S.

Curr Opin Investig Drugs. 2003 Sep;4(9):1095-9. Review.

PMID:
14582454
15.

Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?

López-Farré AJ, Sacristán D, Zamorano-León JJ, San-Martín N, Macaya C.

Cardiovasc Ther. 2008 Spring;26(1):65-74. doi: 10.1111/j.1527-3466.2007.00030.x. Review.

PMID:
18466422
16.

Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.

Miyazaki A, Kanome T, Watanabe T.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec;5(6):463-9. Review.

PMID:
16503866
17.

Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis.

Chang C, Dong R, Miyazaki A, Sakashita N, Zhang Y, Liu J, Guo M, Li BL, Chang TY.

Acta Biochim Biophys Sin (Shanghai). 2006 Mar;38(3):151-6. Review.

18.
19.

Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol.

Warner GJ, Stoudt G, Bamberger M, Johnson WJ, Rothblat GH.

J Biol Chem. 1995 Mar 17;270(11):5772-8.

20.

HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits.

Asami Y, Yamagishi I, Murakami S, Araki H, Tsuchida K, Higuchi S.

Life Sci. 1998;62(12):1055-63.

PMID:
9519807
Items per page

Supplemental Content

Support Center